Pharminent

by Pharmaphorum on February 18, 2019 at 6:00 am

Pfizer and Astellas’ Xtandi has shown it is effective in men with prostate cancer that has spread but The post Trial could unlock new prostate cancer sales for Pfizer/Astellas’ Xtandi appeared first on Pharmaphorum. […]

by PMLiVE RSS Feed: News RSS on February 18, 2019 at 6:00 am

New arrival will face tough competition, not least generic Zytiga […]

by Pharmaphorum on February 18, 2019 at 6:00 am

Bayer has acquired full rights to two drugs partnered with Loxo Oncology, on the same day that the The post Bayer takes control of Loxo duo as Lilly closes takeover appeared first on Pharmaphorum. […]

by Pharmaphorum on February 18, 2019 at 6:00 am

Medicare could soon cover CAR-T therapies under new proposals from the US’ Centers for Medicare & Medicaid Services The post Medicare coverage for CAR-T drugs on the horizon appeared first on Pharmaphorum. […]

by Labiotech.eu on February 18, 2019 at 6:00 am

Next generation sequencing has revolutionized the biotech industry and genomics technology has changed dramatically over the last few years. There are many interesting European genomics companies, but here are 10 we thought especially worthy of […]

by Pharmaphorum on February 18, 2019 at 6:00 am

Drug development can be quite a risky business at the best of times, but particularly in the biotech The post Biotech in post-Brexit Britain: the future for the UK’s pharma-innovation engine? appeared first on Pharmaphorum. […]

by Pharmaphorum on February 18, 2019 at 6:00 am

Analysts are predicting that a combination of Merck’s Keytruda and Pfizer’s Inlyta will become the standard of care The post Keytruda combo set to become “standard of care” in kidney cancer appeared first on Pharmaphorum. […]

by PMLiVE RSS Feed: News RSS on February 18, 2019 at 6:00 am

Company and academic researchers to share one facility […]

by PMLiVE RSS Feed: News RSS on February 18, 2019 at 6:00 am

250m genomes sequenced, but data trapped in silos […]

by PMLiVE RSS Feed: News RSS on February 18, 2019 at 6:00 am

Proposal says it would improve access to CAR-Ts […]

by Pharmaceutical Business review on February 18, 2019 at 6:00 am

PROVENGE (sipuleucel-T) was the first U.S. Food and Drug Administration (FDA)-approved immunotherapy made from a patient’s own immune cells. “We are pleased to work with Dendreon on this The post Decipher Biosciences announces research […]

by Labiotech.eu on February 18, 2019 at 6:00 am

In 1983, the United States Congress passed the Orphan Drugs Act designed to encourage the development of drugs for rare orphan diseases. The EU followed suit in early 2000 as well as a number of other countries. These different legislations have […]

by Labiotech.eu on February 18, 2019 at 6:00 am

One of the biggest Series A rounds in European biotech, €159M ($180M), has been raised by the Swiss company Arvelle Therapeutics to help commercialize its epilepsy drug. Formed just this month, Arvelle plans to submit an application for EMA […]

by BioSpace on February 18, 2019 at 6:00 am

The first trial to test the safety and efficacy of a reversible male contraceptive gel is underway. If approved, this could be the first male hormonal birth control on the market. […]

by PharmaTimes: News RSS on February 18, 2019 at 6:00 am

Lundbeck's Rexulti has failed to achieve the primary endpoint of two Phase III bipolar disorder studies. […]

by Pharmaphorum on February 18, 2019 at 6:00 am

Once the stuff of science fiction, an emerging category of medicine is set to be increasingly influential in The post Defining the digital therapeutics opportunity appeared first on Pharmaphorum. […]

by FDA Law Blog on February 18, 2019 at 6:00 am

By Sara W. Koblitz &mdas […]

by BioSpace on February 18, 2019 at 6:00 am

Being fired, while discouraging in the moment, is not a career killer. In fact, sometimes the jolt of getting that proverbial “pink slip” can actually inspire you take stock of your wider career path and goals as you put yourself back on […]

by Pharmaceutical Business review on February 18, 2019 at 6:00 am

It can also predict what treatment would be most effective for patients following diagnosis. The trial, published in Nature Communications took place at Hammersmith Hospital, part of Imperial The post Artificial intelligence can predict survival of […]

by Pharmaceutical Business review on February 18, 2019 at 6:00 am

The combination of Bavencia and Inlyta have significantly expanded median PFS by more than five months compared against Sutent (sunitinib) as a first-line treatment for patients with advanced The post Bavencio plus Inlyta improves median PFS in […]

by Pharmaphorum on February 18, 2019 at 6:00 am

Adopting an end-to-end commercial content management system has allowed one of the world’s biggest pharmaceutical companies to be The post Case Study: How Shire improved its time-to-market appeared first on Pharmaphorum. […]

by Pharmaphorum on February 18, 2019 at 6:00 am

Over the last ten years the increase in use of digital content and communication throughout pharma has been The post Overcoming the demands of digital content: Is your pharma content approval system ready for the modern age? appeared first on […]

by PMLiVE RSS Feed: News RSS on February 16, 2019 at 6:00 am

Mardene Miller will lead the agency with co-managing director Kevin McHa […]

by BioPharma Dive on February 16, 2019 at 6:00 am

Pfizer and J&J are already on the market with products for non-metastatic prostate cancer. Bayer aims to compete with its drug darolutamide. […]

by Biopharma News on February 16, 2019 at 6:00 am

On Feb. 11, 2019, AbbVie announced a global strategic partnership with Teneobio and its affiliate TeneoOne to develop and commercialize TNB-383B, a B-cell maturation antigen (BCMA)-targeting immunotherapeutic for the potential treatment of multiple […]